RTSL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RTSL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Rapid Therapeutic Science Laboratories's Earnings per Share (Diluted) for the three months ended in Jun. 2023 was $0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.01.
Rapid Therapeutic Science Laboratories's EPS (Basic) for the three months ended in Jun. 2023 was $0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.01.
Rapid Therapeutic Science Laboratories's EPS without NRI for the three months ended in Jun. 2023 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.13.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
The historical data trend for Rapid Therapeutic Science Laboratories's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Therapeutic Science Laboratories Annual Data | |||||||||||||||||||||
Trend | Mar13 | Mar14 | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Dec21 | Dec22 | |||||||||||
EPS (Diluted) | Get a 7-Day Free Trial | -26.00 | -7.25 | -0.25 | -0.38 | -0.23 |
Rapid Therapeutic Science Laboratories Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
EPS (Diluted) | Get a 7-Day Free Trial | -0.01 | -0.03 | 0.01 | 0.02 | 0.01 |
For the Medical Devices subindustry, Rapid Therapeutic Science Laboratories's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Rapid Therapeutic Science Laboratories's PE Ratio distribution charts can be found below:
* The bar in red indicates where Rapid Therapeutic Science Laboratories's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Rapid Therapeutic Science Laboratories's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as
Diluted EPS (A: Dec. 2022 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-1.795 | - | 0) | / | 7.747 | |
= | -0.23 |
Rapid Therapeutic Science Laboratories's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as
Diluted EPS (Q: Jun. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (0.046 | - | 0) | / | 8.318 | |
= | 0.01 |
EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Therapeutic Science Laboratories (OTCPK:RTSL) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Rapid Therapeutic Science Laboratories's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Henry Anthony Punzi | director | 1932 WALNUT PLAZA, CARROLLTON TX 75006 |
Scott Suggs Justin | director | 639 SWORD BRIDGE DR., LEWISVILLE TX 75056 |
Sean Paul Berrier | 10 percent owner | 7108 DUFFIELD DR., DALLAS TX 75248 |
Schmidt Donal Ray Jr. | director, 10 percent owner, officer: President and CEO | 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240 |
Ryan Casey Johnson | director, officer: Chief Operating Officer | 2307 CASTLE ROCK RD, CARROLTON TX 75007 |
Texas Mdi, Inc. | 10 percent owner | 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240 |
D Hughes Watler | director, officer: CFO | 2323 S. VOSS ROAD, STE. 510-12, HOUSTON TX 77057 |
Steve Bond | director, officer: CFO | 28839 PUJOL ST., #832, TEMECULA CA 92590 |
Brent Willson | director, officer: CEO and President | 5271 CAMINITO EXQUISITO, SAN DIEGO CA 92130 |
From GuruFocus
By Marketwired Marketwired • 06-23-2020
By Marketwired Marketwired • 08-18-2020
By GuruFocusNews GuruFocusNews • 04-28-2022
By Value_Insider Value_Insider • 12-13-2022
By Marketwired Marketwired • 10-06-2021
By Marketwired Marketwired • 12-03-2020
By Marketwired Marketwired • 10-07-2021
By Marketwired Marketwired • 08-02-2021
By Marketwired Marketwired • 06-10-2020
By GuruFocusNews GuruFocusNews • 12-02-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.